Table 2.
Outcomes of antiviral therapy, as indicated by the mean reduction in serum DNA, HBV DNA suppression, undetectable HBV-DNA, and HBe seroconversion.
| TLV (39) | ETV (47) | P value | |
|---|---|---|---|
| HBV DNA (log10 IU/mL) | |||
| 4th week | 3.32 ± 0.80 | 3.64 ± 1.06 | 0.228 |
| 12th week | 2.94 ± 0.96 | 2.54 ± 1.02 | 0.253 |
| 24th week | 2.24 ± 1.39 | 1.9 ± 0.82 | 0.348 |
| HBV DNA suppression, (below 2000 IU/mL) | |||
| 4th week | 13/31 (41.9%) | 15/32 (46.8%) | 0.444 |
| 12th week | 11/14 (78.6%) | 22/27 (81.5%) | 0.565 |
| 24th week | 9/11 (81.8%) | 28/32 (87.5%) | 0.488 |
| Nondetectable HBV DNA (below 20 IU/mL) | |||
| 4th week | 0/31 | 0/32 | |
| 12th week | 3/14 (21.4%) | 5/27 (18.5%) | 0.583 |
| 24th week | 2/11 (18.1%) | 12/32 (37.5%) | 0.213 |
| HBeAg seroconversion | |||
| 4th week | 2/21 (9.5%) | 0/25 | 0.119 |
| 12th week | 0/14 | 2/27 (7.4%) | 0.248 |
| 24th week | 0/11 | 0/32 | |
| Antiviral resistance | 0 | 0 | |
| Hepatitis flare up | 0 | 0 |
Variables are expressed as mean ± standard deviation (SD) or n/N (%). Hepatitis flare up was defined as the elevation of alanine aminotransferase (ALT) level to more than 10 times the upper normal limit. TLV, telbivudine; ETV, entecavir; and HBeAg, hepatitis B e antigen.